We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 343

Application for Prohibition Granted for Generic Version of Concerta
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

The Court granted Janssen's application prohibiting the Minister of Health from issuing an NOC to Actavis for its generic version of Concerta. The


Supreme Court Updates - Intellectual Property Weekly Abstracts - Week of January 16, 2017
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

The Supreme Court of Canada announced that judgment in this application for leave to appeal will be delivered on Thursday, January 19, 2017. The


Patent Validity and Infringement Upheld on Appeal; Limitation Period in Patent Act not Necessarily Applicable to Old Act Patents
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

In this case, the FCA considered an appeal and cross-appeal of a decision relating to omeprazole. The trial decision can be found here (2015 FC 322


Successful Defendant Awarded Costs Elevated by 50 for Most Issues and on Solicitor-and-Client Basis for Withdrawn Punitive Damages Claim
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

In this infringement action, the Court held the patent at issue valid and not infringed. The Court noted that there were unusual developments over the


Dismissed Motion for Interlocutory Injunction Upheld on Appeal
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

This was an appeal against Justice Manson's unreported decision in 2016 FC 606, dismissing TearLab's motion for an interlocutory injunction to prevent


Court awards $6.5 million for plaintiffs' costs following successful infringement action
  • Borden Ladner Gervais LLP
  • Canada
  • December 14 2016

The Court awarded the Plaintiffs a lump sum payment of $6.5 million for their costs in this case. The amount consisted of $2.9 million for legal fees


Prohibition granted re the compound patent; dismissed re use and polymorph patents
  • Borden Ladner Gervais LLP
  • Canada
  • May 30 2014

This NOC proceeding deals with challenges to three patents, a compound patent, a use patent and a polymorph patent


Motion for default judgment denied without affidavit evidence
  • Borden Ladner Gervais LLP
  • Canada
  • October 28 2013

The Plaintiffs brought a motion for default judgment after no Statement of Defence was filed and no response to the Request to Admit was provided. The


Appeal of a decision to not strike out Statement of Claim in its entirety dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • April 6 2016

The Court dismissed Teva Canada Limited's appeal from the Prothonotary's Order declining to strike out Gilead's Statement of Claim in its entirety


Court Grants Order Correcting Inventorship, but Declines to Order Recording of Documents at Patent Office
  • Borden Ladner Gervais LLP
  • Canada
  • October 12 2016

Qualcomm sought an order pursuant to s. 52 of the Patent Act to add Mr. Rychlik as the sole inventor and to remove two of the named inventors. The